You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

April 8, 2020

Laos Issues COVID-19 Regulations for Freight, Insurance, Mineral Processing, Hydropower, and Healthcare Industries

Subscribe to Updates

Cross-Border Transportation of Goods

The National Taskforce Committee for COVID-19 Prevention and Control has issued Guideline No. 020, Regarding Prime Minister’s Order No.02/PM, dated April 2, 2020, which includes directives aimed at the freight sector. The transportation of goods is one of the few operations that is still permitted to cross the Lao border, although this is subject to the following regulations:

  • The importation of goods by vehicles is authorized up to the loading point closest to the port of entry. Once the goods have been unloaded, the vehicle must depart immediately. Before entering Laos the driver must fill out a health form and undergo an examination, as recommended by the National Taskforce Committee for COVID-19 Prevention and Control.
  • For the transportation of goods that transit through Laos before being exported to a third country, vehicles can proceed to the loading point in Laos and onward to their destination. If it is necessary to use a vehicle from the country of origin to reach the destination, the vehicle must be sprayed with a disinfectant in accordance with the specified rules. Foreign drivers are also prohibited, so the driver must be a Lao national.

Insurance Operations

On March 31, 2020, the Department of State Enterprise Investment Management and Insurance, which is under the Ministry of Finance, issued Notification No. 0338, which provides the following measures:

  • Deferment of the deadline for submission of insurance company financial reports and other reporting duties relating to the operation of insurance businesses for the year 2019. The new submission deadline is April 30, 2020.
  • Requirement for life insurance and health insurance policies that have already been sold to also cover COVID-19-related symptoms, in accordance with the amount and duration of coverage agreed upon in the contract.
  • Requirement for all insurance companies to devise a plan to form teams of employees to work in their offices from April 1 to April 19, 2020, and to support other employees to work remotely. Alternatively, companies can devise a specific schedule for each employee to come to work on an alternating basis, in order to prevent the spread of the COVID-19. Insurance companies are also requested to ensure they can receive claims while the COVID-19 outbreak measures are in place.

Factories that Process Minerals and Hydropower Plants under Construction

On April 5, 2020, the Ministry of Mines and Energy issued Notification 0432/MEM, which orders hydropower plant construction projects and factories involved in exploration for and processing of minerals to suspend their activities from April 1 to April 19.

Until April 19, these operations are required to proceed as follows:

  • Manage their staff and personnel who are currently renting and staying in accommodation within the factory, and follow measures issued by the government. Employees and personnel should not leave the factory premises, or their accommodations, if it is not necessary (a phrase that is not yet defined). Employees and personnel must be prohibited from traveling to local places where there is a risk of contracting the virus.
  • Disseminate information about COVID-19 to employees and personnel on-site in order to prevent and combat the spread of the virus, in accordance with recommendations issued by the local authorities. Any employee who displays symptoms of the virus should be separated from the other employees, and the supervisor should immediately contact the emergency number (166 or 020-5406-6777) in order to implement the recommendations issued by the National Task Force.
  • Ensure that social distancing of two meters is strictly observed by all employees, provide masks, and ensure that soap is available for washing hands, or disinfectant is provided to kill the virus, in accordance with the recommendations of the National Task Force.
  • Disinfect the premises, including production sites, canteens, and accommodations, along with other areas where there is a risk of the virus spreading.

Facilities that have been closed and adversely impacted by COVID-19 should report the impact to the Ministry of Energy and Mines, and the related authorities, as indicated in Prime Minister’s Order No. 06/PM, dated March 29, 2020. In addition, the ministry welcomes comments regarding this notification from stakeholders and from the public and private sectors.

Private Hospitals and Clinics Prohibited from Treating COVID-19

Out of a concern about some private caregiving facilities in the country being inadequately equipped to handle the epidemic, on April 2, 2020, the Ministry of Health issued Notification 0413/MOH, ordering private hospitals and treatment facilities not to attempt treatment of COVID-19 patients (with limited exceptions for international-standard private hospitals). 

This notification followed the issuance of previous measures seemingly announcing the closure of private hospitals and private treatment centers. Together, however, these regulations mean that  specialized clinics and private hospitals can provide their usual medical services, but they are not allowed to attempt treatment of COVID-19 patients; if a case of COVID-19 is suspected, they should call the emergency hotline immediately.

For more details on these measures, or on any aspect of Laos’ response to the COVID-19 pandemic, please contact Dino Santaniello at [email protected].

Related Professionals

Industries

Aviation

Energy

Insurance

Life Sciences

Practices

Corporate/M&A

Regulatory Affairs

Location

RELATED INSIGHTS​ 

August 14, 2026
Thailand’s Office of the Insurance Commission (OIC) has issued guidelines clarifying the boundaries between permissible and prohibited activities for unlicensed individuals—including influencers, bloggers, and content creators—when communicating about insurance products on social media. The Good Practice Guidelines for Persons Not Licensed as Insurance Agents or Brokers Regarding the Dissemination of Insurance Content Through Digital Media B.E. 2569 (2026) took effect on July 24, 2026. Activities Requiring a License The guidelines reserve the following activities for licensed agents and brokers: Soliciting or facilitating insurance contracts. Providing personalized advice on product suitability. Recommending policy cancellation to purchase promoted products. Creating links that facilitate contract formation. Receiving performance-based compensation tied to policies or premiums generated. Importantly, boilerplate disclaimers such as “this is not a recommendation to buy insurance” will not shield individuals from liability if the OIC views the content as personalized advice or solicitation. Permitted Activities Unlicensed persons may present general educational content about insurance—such as explaining terminology, sharing industry statistics, reporting news, or sharing personal experiences—provided the content does not target specific individuals to purchase from specific companies. The guidelines also set out best practices for communication, including presenting information in a fair and balanced manner that covers both benefits and limitations, encouraging consumers to read policy terms and consult licensed professionals, verifying information from credible sources before dissemination, and exercising special care when the audience may include vulnerable groups such as persons aged 60 and older. Prohibited Practices Prohibited practices include fear-based marketing, creating artificial urgency, omitting material limitations, making exaggerated claims, falsely claiming professional credentials, using fake engagement mechanisms, and sharing false or misleading content. The guidelines also reinforce the prohibitions under section 83 of the Life Insurance Act B.E. 2535 and section 78 of the Non-Life Insurance Act B.E. 2535 against soliciting insurance contracts with foreign operators
Read More
August 10, 2026
On June 17, 2026, Indonesia’s National Agency of Drug and Food Control (BPOM) issued BPOM Regulation No. 10 of 2026 on Nutritional Information on Processed Food Labels. The new regulation, which revokes three previous nutrition labeling regulations, introduces several notable changes affecting food and beverage manufacturers, importers, and distributors. These changes range from updated nutrient reference values and serving-size requirements to the introduction of the Nutri-Level front-of-pack labeling system for certain beverage products. Businesses operating in Indonesia should carefully review these developments and assess their products’ compliance with the new requirements during the transition period. Implementation of the Nutri-Level Labeling System To implement the recently issued decree on Nutri-Level labeling, BPOM Regulation No. 10 of 2026 stipulates the requirements to implement the Nutri-Level labeling system on the front-of-pack. Under the new framework, ready-to-drink beverages, powdered beverages, and liquid or solid concentrates are required to display Nutri-Level labeling on the front label of their packaging. The Nutri-Level labeling system classifies products into color-coded levels A through D based on their sugar, sodium, and total fat content. The applicable Nutri-Level is determined based on the lowest level measured in the assessment of sugar, sodium, and total fat content. For products classified as level C or D, the Nutri-Level label must be accompanied by information on the relevant sugar, sodium, and total fat content per 100 ml of the ready-to-consume product. Products classified as level A or B may either display only the Nutri-Level designation or display the Nutri-Level together with the relevant nutritional information per 100 ml. Minimum Vitamin and Mineral Content Required for Declaration BPOM Regulation No. 10 of 2026 introduces a stricter threshold for the declaration of vitamins and minerals in the nutritional value information section (ING). Vitamins or minerals may only be declared if they are present at a
Read More
August 10, 2026
The drug registration process in Vietnam will be simplified, particularly for foreign applicants, following the recent issuance by Vietnam’s Ministry of Health (MOH) of a new circular that is expected to reduce administrative hurdles. Circular No. 32/2026/TT-BYT on the registration of drugs and medicinal ingredients (Circular 32) was issued on July 29, 2026, and will take effect on October 1, 2026, replacing Circular No. 12/2025/TT-BYT. Key provisions of the new circular are discussed below. Five-Year Data Exclusivity and Five-Month Public Disclosure Framework Circular 32 updates data protection guidelines by explicitly referencing Article 128 of the amended Intellectual Property Law, which sets out that new drugs supported by clinical trial data submitted for the first time will be granted a five-year data exclusivity period from the date of the initial marketing authorization (MA) approval. Subsequent applications that rely on the originator’s protected data will not be eligible for approval from the date of submission of the originator’s registration dossier until five years after the first MA is granted. Furthermore, in accordance with the new regulations, the regulatory authority must publicly disclose information on subsequent applications five months before the granting of MA, providing originator companies with an opportunity to exercise and enforce their intellectual property rights. Simplified Requirements for Foreign Legal Documents Circular 32 expands the circumstances under which legal documents issued by foreign authorities are exempt from consular legalization and authenticity verification requirements. Specifically, such documents may be exempt if the Drug Administration of Vietnam (DAV) is able to verify their authenticity directly through official electronic means, including written confirmation or email correspondence sent directly to the MOH by the competent foreign authority, or publicly accessible English-language databases maintained by recognized foreign regulatory authorities. In addition, the new circular permits the submission of electronic notarized copies of legal documents
Read More
July 24, 2026
As food innovation continues to accelerate, manufacturers are increasingly introducing ingredients derived from new sources, produced using novel technologies, or lacking a significant history of human consumption. While these innovations create new opportunities for the food industry, they also raise important questions regarding consumer safety. For this reason, many jurisdictions, including Thailand, the European Union, Australia and New Zealand, Canada, and Singapore, require a premarket safety assessment for novel food ingredients before they can be placed on the market. The objective of this assessment is to ensure that each ingredient is safe for its intended use and level of consumption, does not present toxicological, allergenic, microbiological, or nutritional concerns, and will not mislead consumers. Scientific authorities typically evaluate the ingredient’s identity, manufacturing process, composition, specifications, anticipated dietary exposure, toxicological information, nutritional impact, and history of use before determining whether it can be marketed. Against this background, the Thai Food and Drug Administration (FDA) recently took an important step toward improving regulatory transparency by publishing, for the first time, a consolidated public list of substances that have successfully completed the Thai FDA’s safety assessment process, including substances determined to be novel foods and those determined not to fall within the novel food category. The list identifies the approved substances, the corresponding manufacturers or importers, approval dates, and the approved conditions of use. Although the publication does not change the existing legal framework governing novel food approvals, it provides businesses with greater visibility into the Thai FDA’s regulatory precedents and the types of substances that have previously been accepted through the safety assessment process. The full announcement is available on the Thai FDA’s website. As the list is now publicly available, it also provides useful insight into the types of substances that have successfully completed the Thai FDA’s safety assessment process.
Read More